logo
VALIDITY OF THE MINIMUM-DATA-SET-BASED QUALITY INDICATOR FOR DETERMINING THE PREVALENCE OF ANTIPSYCHOTIC MEDICATION USAGE AMONG LOW RISK NURSING HOME RESIDENTS
TRANSLATING EVIDENCE TO PRACTICE IN BREAST CANCER
REGIONAL VARIATION IN PRESCRIPTION USE IN THE UNITED STATES
BRIEF ASSESSMENT OF PRIORITY SYMPTOMS IN HORMONE REFRACTORY PROSTATE CANCER (HRPCA)
RESOURCE CONSUMPTION RELATED TO MUCOSITIS IN LYMPHOMA PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS PBPC TRANSPLANTATION
AN ECONOMIC MODEL FOR THE PHARMACOLOGICAL MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER IN THE US
ESTIMATING THE IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES
A SIX YEAR FOLLOW-UP STUDY OF THE RELATIONSHIP BETWEEN MORTALITY, HOSPITALISATION AND ADHERENCE TO STATIN TREATMENT AFTER FIRST MYOCARDIAL INFARCTION
VASOPEPTIDASE INHIBITOR REDUCES IN-HOSPITAL COSTS FOR CONGESTIVE HEART FAILURE PATIENTS
IMPACT OF CENSORED COST DATA ON THE OUTCOMES OF ECONOMIC EVALUATIONS
HANDLING MISSING DATA IN STOCHASTIC COST-EFFECTIVENESS ANALYSIS
THE COST OF UPPER GASTRODUODENAL ENDOSCOPY
PRICING OF PHARMACEUTICALS IN CANADA AND EUROPE
USE OF THE SOJA METHOD FOR CHOOSING A HMG CO-A REDUCTASE INHIBITOR (STATIN) IN IRELAND
THE IMPACT OF PIPELINE DRUGS ON UNITED STATES DRUG EXPENDITURE GROWTH TRENDS
THE IMPACT OF THE DIAGNOSIS OF CANCER ON OUT-OF-POCKET HEALTH-CARE EXPENDITURES MADE BY THE US ELDERLY
A SPECIFIC QUALITY OF LIFE SCALE IN UPPER LIMB LYMPHOEDEMA
MEN'S PREFERENCES FOR THE CONSERVATIVE MANAGEMENT OF NON-METASTATIC PROSTATE CANCER
COMPARISON BETWEEN INVESTIGATOR AND PATIENT'S GLOBAL HEALTH ASSESSMENTS USING CALCULATED HUI-III AND SF-36 UTILITY VALUES
ORLISTAT IN OBESE TYPE 2 DIABETIC PATIENTS
EXCESS MORBIDITY AND COST OF FAILING TO ACHIEVE TARGETS FOR BLOOD PRESSURE CONTROL IN THE ELDERLY
PATIENT-REPORTED OUTCOMES
POWER CALCULATIONS FOR WIDELY USED PATIENT-REPORTED OUTCOMES (PRO) MEASURES IN WOMEN'S HEALTH TRIALS
DESIGN AND ANALYSIS OF UNIT COST ESTIMATION STUDIES
ESTIMATING HEALTH-CARE COSTS ASSOCIATED WITH DIABETES-RELATED COMPLICATIONS USING DATA FROM THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS)
BOTTOM UP VERSUS TOP DOWN COST ESTIMATES FOR TYPE 2 DIABETES
A DYNAMIC, THREE-PART MODEL FOR PREDICTING HOSPITAL COSTS IN TYPE 2 DIABETIC PATIENTS
ESTIMATING THE POTENTIAL HEALTH GAIN AND COST CONSEQUENCES OF INTRODUCING A PRE-SCHOOL DTPA PERTUSSIS BOOSTER INTO THE UK CHILD VACCINATION SCHEDULE
THE ECONOMIC BURDEN OF VIRAL RESPIRATORY INFECTION IN THE UNITED STATES
THE OBSERVED COSTS AND HEALTH-CARE USE OF CHILDREN IN A RANDOMIZED CONTROLLED TRIAL OF PNEUMOCOCCAL CONJUGATE VACCINE
SOAP-51
EFFICACY OF NURSE TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN PRIMARY CARE
RECENT WEIGHT GAIN AND THE COST OF ACUTE SERVICE USE AMONG INDIVIDUALS WITH SCHIZOPHRENIA
CAN HEALTH STATE VALUES BE PREDICTED FROM HEALTH-RELATED QUALITY OF LIFE MEASURES?
ESTIMATING PATIENTS' PREFERENCES IN TREATMENT CHOICES INVOLVING RISK
PSYCHOMETRIC PERFORMANCE OF THE MEDICAL OUTCOMES STUDY SLEEP SCALE IN THE US GENERAL POPULATION
SLEEP DISORDERS AND HEALTH RELATED QUALITY OF LIFE—AN EPIDEMIOLOGICAL SURVEY
COST OF THE FIRST, SECOND AND SUBSEQUENT EPISODE OF DEPRESSION IN POLAND
MODELLING THE COSTS OF ILLNESS AND THE COSTS OF RELAPSE IN THE MANAGEMENT OF SCHIZOPHRENIA IN THE UK
INDIRECT COSTS DUE TO BACK PAIN IN THE UNITED STATES
ASSESSING THE QUALITY OF LIFE IN PARKINSON'S DISEASE
COST-EFFECTIVENESS OF CABERGOLINE COMPARED TO LEVODOPA IN EARLY PARKINSON'S DISEASE IN SWEDEN
DEVELOPMENT OF A MINIMUM DATASET (MDS)-BASED COMORBIDITY INDEX FOR A NURSING HOME POPULATION
TRANSITION IN HEALTH-RELATED QUALITY OF LIFE IN U.S. ELDERLY
TRENDS IN POPULATION-BASED HEALTH-RELATED QUALITY OF LIFE
DOES ILLNESS-RELATED LOST PRODUCTIVE WORK TIME VARY BY JOB DEMAND OR JOB CONTROL
THE NET COST OF ASTHMA TO A US PUBLIC MEDICAID PROGRAM
PREPARING THE ASTHMA SYMPTOM UTILITY INDEX FOR INTERNATIONAL USE
SELF-REPORT OF HEALTH-RELATED LOST PRODUCTIVE TIME AT WORK
SMOOTHED BOOTSTRAP FOR CONFIDENCE INTERVAL FOR COST-EFFECTIVENESS RATIOS
INCORPORATING CLINICAL LEVEL-OF-EVIDENCE CRITERIA INTO A BREAST CANCER TREATMENT MODEL FOR JAPAN
MARKOV MODELLING TO CONVERT TRIAL-BASED COST-EFFECTIVENESS INFORMATION TO OTHER COUNTRIES—THE TIOTROPIUM EXAMPLE
A PROBLEM WITH STOCHASTIC ECONOMIC EVALUATION WHEN THE TIME HORIZONS FOR THE COST AND EFFECTIVENESS MEASUREMENTS ARE ASYMMETRICAL
ESTIMATING AND COMPARING RESOURCE USE AND COST OF G-CSF USE IN CHEMOTHERAPY WITH THE ACTIVITY-BASED COSTING (ABC) METHOD IN THREE SETTINGS
PROBABILISTIC SENSITIVITY ANALYSIS FOR EVALUATING COST-UTILITY OF ENTACAPONE TREATMENT FOR PARKINSON'S DISEASE
DO HEALTH CARE PURCHASERS PREFER PAYING FOR LIFE EXTENSION OR QUALITY OF LIFE IMPROVEMENT?
USE OF AN AUTOMATED PROCESS TO SCAN AND INTERPRET MANUALLY-CODED DATA FORMS IN PHARMACOECONOMICS RESEARCH
THE ‘NICE’ APPROACH TO PHARMACOECONOMICS
FEASIBILITY OF A DATABASE APPROACH TO ADHERENCE WITH OSTEOPOROSIS THERAPY
CAREGIVER-BURDEN MEASURES IN ALZHEIMER'S DISEASE
A COMPARISON OF EQ-5D TIME TRADE-OFF VALUES OBTAINED IN GERMANY, UK AND SPAIN
TO TRANSLATE OR TO ADAPT – WHAT DO THE QUESTIONS MEAN?
COST ANALYSIS FOR END-OF-LIFE CARE
VALUATION OF INFORMAL CARE
WITHDRAWN
MODELING ANTIBIOTIC EFFICACY BY INFECTIOUS AGENT AND PROBABILITY OF RESISTANCE
COST-EFFECTIVENESS OF TUBERCULOSIS PREVENTIVE THERAPY IN HIV-INFECTED PATIENTS
A REAL OPTION APPROACH TO VALUING PHARMACEUTICAL INVESTMENTS AND FIRMS
ESTIMATING INFLUENZA-RELATED EXCESS HOSPITAL ADMISSIONS
MICE (MODULE FOR STANDARDISED INDIRECT COST ESTIMATION) INCREASES THE TRANSFERABILITY OF STUDY RESULTS
CHANGING STRATEGIES IN THE PROMOTION OF HEALTH CARE RESEARCH IN GERMANY
QUALITY OF LIFE
THE RELATION OF DISTRIBUTION- AND ANCHOR-BASED APPROACHES ON INTERPRETATION OF CHANGES IN HEALTH-RELATED QUALITY OF LIFE
ASSESSMENT OF RESPONDENT ACCEPTABILITY OF UTILITY MEASURES
FACTORS INFLUENCING COMPLETION OF THE EUROQOL EQ-5D GENERIC QOL QUESTIONNAIRE
BASELINE ANEMIA AND RISK OF POOR RESPONSE TO CHEMOTHERAPY IN INTERMEDIATE GRADE NON-HODGKIN'S LYMPHOMA (IGNHL) PATIENTS
COST OF TREATMENT AND FOLLOW UP OF BREAST CANCER. A RETROSPECTIVE EVALUATION IN A COMPREHENSIVE CANCER CENTRE
USING LEVEL OF EVIDENCE CRITERIA IN THE EVALUATION OF PHARMACOECONOMIC RESULTS
COST-EFFECTIVENESS OF URATE OXIDASE IN PREVENTION AND TREATMENT OF SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES
FIRST-LINE THERAPY FOR ADVANCED BREAST CANCER – COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN
MODELLING THE COST-EFFECTIVENESS OF DOCETAXEL IN THE SECOND LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC)
COST OF THE POST-PBPC REINFUSION PERIOD IN HIGH DOSE TREATMENT OF NON-HODGKIN'S FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM
COST OF MANAGING SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES
COST-EFFECTIVENESS OF IMAGE-GUIDED VERSUS BLIND INSERTION OF HICKMAN LINES IN ADULT CANCER PATIENTS BY NURSES
COST OF HOSPITALIZATION FOR THORACIC SURGERY IN PATIENTS WITH LUNG CANCER IN GREECE
COST-EFFECTIVENESS OF SENTINEL LYMPH NODE MAPPING AND ADJUVANT INTERFERON THERAPY FOR STAGE II MELANOMA
THE RELATIONSHIP OF AGE AND DURATION OF HORMONAL THERAPY USE AMONG PATIENTS DIAGNOSED WITH CANCER OF THE PROSTATE
PHARMACOECONOMIC ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH DOCETAXEL-CISPLATIN, PACLITAXEL-CISPLATIN AND PACLITAXEL-CARBOPLATIN
CHEMOTHERAPY-INDUCED NEUROPATHY IN OVARIAN CANCER COST EFFECTIVENESS ANALYSIS
QOL CHANGE OVER TIME POST-REINFUSION OF PBPC IN HIGH DOSE TREATMENT OF NONHODGKIN'S FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM USE
ELAPSED TIME TO DISCLOSURE OF BRCA1/2 GENETIC TESTING RESULTS AND PARTICIPANTS' DISTRESS
PSYCHOMETRIC PROPERTIES OF THE EORTC QUALITY OF LIFE CORE QUESTIONNAIRE (QLQ-C30) IN EORTC TRIALS
QUALITY OF LIFE IN CANCER CLINICAL TRIALS – AN OVERVIEW OF APPROACHES WITHIN THE EORTC
CHOICE OF OPTIMAL ANTI-EMETIC STRATEGIES IN CANCER THERAPY
IMPACT OF INFLUENZA AND TREATMENT WITH OSELTAMIVIR ON INDIVIDUALS' DAILY ACTIVITIES AND RETURN TO NORMAL ACTIVITY
COST-EFFECTIVENESS OF HIV-SCREENING OF PATIENTS ATTENDING A CLINIC FOR SEXUALLY TRANSMITTED DISEASES IN AMSTERDAM
THE IMPACT OF DRUG COMPLIANCE ON THE COST OF TREATING HIV/AIDS IN AFRICA
A RETROSPECTIVE ANALYSIS OF TREATMENT PATTERNS AND COSTS IN EXTERNAL GENITAL WARTS FOR THE NETHERLANDS
COST-UTILITY ANALYSIS OF A PNEUMOCOCCAL/MENINGOCOCCAL COMBINATION VACCINE FOR INFANTS
ESTIMATED COSTS TO CONDUCT A PHASE III CLINICAL TRIAL OF A NEW PULMONARY TUBERCULOSIS DRUG
PHARMACOECONOMIC EVALUATION OF IMIQUIMOD (ALDARA) FOR THE TREATMENT OF EXTERNAL GENITAL WARTS IN A DUTCH TREATMENT ENVIRONMENT
A COST-BENEFIT ANALYSIS OF INFLUENZA VACCINATION IN A COMPANY IN ITALY (ENI SPA)
COST-BENEFIT ANALYSIS OF VACCINATING HEALTHY WORKING ADULTS AGAINST INFLUENZA IN THE NETHERLANDS
DEVELOPMENT AND VALIDATION OF A 17-COUNTRY EUROPEAN PHARMACOECONOMIC MODEL
A COST BENEFIT ANALYSIS OF TWO ALTERNATIVE MASS IMMUNIZATION PROGRAMS WITH A CONJUGATE VACCINE AGAINST MENINGOCCOCAL DISEASE TYPE C
BURDEN OF ILLNESS IMPOSED BY SEVERE SEPSIS IN GERMANY
CAN VARICELLA BE ELIMINATED BY UNIVERSAL CHILDHOOD VACCINATION COST-BENEFICIALLY? EXAMPLES FOR EUROPE
A STUDY ON THE HEALTH EFFECTS OF FLU AND FLU-LIKE ILLNESSES IN THE WORKING POPULATION AND THEIR COST IMPACT ON A BIG CORPORATION IN HONG KONG
ECONOMIC COMPARISON OF SEQUENTIAL (IV TO PO) CIPROFLOXACIN/ METRONIDAZOLE VS PIPERACILLIN/TAZOBACTAM FOR THE TREATMENT OF PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS
COST-EFFECTIVENESS OF TERBINAFINE AND ITRACONAZOLE IN TOENAIL ONYCHOMYCOSIS IN POLAND
HOW CAN PRODUCTS WITH MARGINAL EFFICACY SAVE MONEY? THE EXAMPLE OF A NON SPECIFIC, IMMUNOSTIMULATING, PREVENTIVE TREATMENT FOR RECURRENT UPPER RESPIRATORY TRACT INFECTIONS IN CHILDREN
DIRECT AND INDIRECT COSTS OF RESPIRATORY INFECTIONS
POTENTIAL USE OF FLUOROQUINOLONES IN THE TREATMENT OF PULMONARY TUBERCULOSIS
ESTIMATING THE RETURN ON INVESTMENT FOR TUBERCULOSIS DRUGS
ANTIBIOTIC PROPHYLAXIS IN TOTAL HIP REPLACEMENT SURGERY
PROPHYLAXIS AGAINST RSV, VARICELLA AND PNEUMOCOCCAL INFECTIONS
THE FIRST STEP TO GENERATING UTILITY FROM QUALITY OF LIFE
THE DEVELOPMENT AND VALIDATION OF THE INFLUENZA DAILY DISRUPTION QUESTIONNAIRE (IDDQ)
COST-EFFECTIVENESS ANALYSIS OF THREE SURGICAL TREATMENTS FOR FEMALE STRESS URINARY INCONTINENCE
AN ECONOMIC MODEL OF UNSTABLE BLADDER IN ITALY
CUMULATIVE INCIDENCE AND TOTAL COSTS ASSOCIATED WITH URINARY AND OVERACTIVE BLADDER DISORDERS IN EMPLOYED POPULATIONS
COST-MINIMISATION STUDY COMPARING SIMULECT VERSUS THYMOGLOBULINE IN RENAL TRANSPLANT INDUCTION
HEALTH-RELATED CONSEQUENCES AND COSTS OF OVERACTIVE BLADDER
INTERNATIONAL PSYCHOMETRIC VALIDATION AND CROSS-CULTURAL EQUIVALENCE OF A URINARY INCONTINENCE SPECIFIC QOL SCALE (CONTILIFE®) IN SIX EUROPEAN COUNTRIES
RIGOROUS CRITERIA FOR TREATMENT RESPONSE DIFFERENTIATED EFFICACY OF OLANZAPINE VERSUS HALOPERIDOL IN PATIENTS WITH SCHIZOPHRENIA
IMPROVEMENT IN QUALITY OF LIFE AND DEPRESSIVE SYMPTOMS IN SCHIZOPHRENIC PATIENTS IS ASSOCIATED WITH ROBUST ACUTE TREATMENT RESPONSE OF OLANZAPINE VERSUS HALOPERIDOL
PATIENT MEDICATION ATTITUDE AFTER SWITCHING TO ZIPRASIDONE FROM OTHER ANTIPSYCHOTICS
DRUG SELECTION, DOSING, AND UTILIZATION PATTERNS AMONG DEPRESSED PATIENTS TREATED WITH SSRI'S AND VENLAFAXINE IN US MANAGED CARE PLANS
THE COST-EFFECTIVENESS OF QUETIAPINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS PARTIALLY RESPONSIVE TO PREVIOUS ANTIPSYCHOTICS–AN ECONOMIC ANALYSIS OF THE PRIZE STUDY
PATTERNS OF COMORBIDITIES AND COPRESCRIBING AMONG DEPRESSED PATIENTS TREATED WITH SSRI'S AND VENLAFAXINE IN US MANAGED CARE PLANS
CHANGES IN SCHIZOPHRENIA-RELATED TOTAL DIRECT MEDICAL COSTS FOLLOWING INITIATION OF OLANZAPINE OR RISPERIDONE IN A PRIVATELY INSURED POPULATION IN THE UNITED STATES
SCHIZOPHRENIA OUTCOMES RESEARCH STUDY IN SPAIN
ECONOMIC ANALYSIS OF PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER
MANAGEMENT AND COST OF A MANIC EPISODE IN BIPOLAR DISORDER–A FRENCH STUDY
RETROSPECTIVE ECONOMIC EVALUATION OF MIRTAZAPINE, VENLAFAXINE XR AND SERTRALINE IN A MANAGED CARE POPULATION
THE COST OF TREATING SCHIZOPHRENIA IN ROUTINE CLINICAL PRACTICE
THE DIRECT COST OF RISPERIDONE VERSUS HALOPERIDOL THERAPY FOR CHRONIC SCHIZOPHRENIA IN POLAND
ANTIPSYCHOTIC COMPLIANCE EVALUATION – A POPULATION-BASED, MANAGED-CARE STUDY OF PERSISTENCE WITH INITIALLY PRESCRIBED ANTIPSYCHOTIC MEDICATION
THE IMPACT OF ALCOHOL ABUSE ON EMPLOYMENT IN SWITZERLAND
ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
LONG-TERM ECONOMIC BENEFITS OF ANTIPSYCHOTIC USE
DEPRESSION AND QUALITY OF LIFE AND THEIR EFFECT ON HEALTH-CARE UTILIZATION
IDENTIFICATION AND ONE-YEAR COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CLAIMS DATA ANALYSIS
COMPARISON OF ADVERSE DRUG EVENTS (ADE) ASSOCIATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) IN TWO MANAGED CARE ORGANIZATIONS (MCO)
CLINICAL AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH OLANZAPINE IN PATIENTS WITH BIPOLAR DISORDER AS COMPARED WITH HALOPERIDOL
WITHDRAWN
THE USE OF NEFAZODONE IN THE TREATMENT OF POST TRAUMATIC STRESS DISORDER
HEALTH-CARE RESOURCE USE AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA
MENTAL WELL-BEING AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA
A COMPARISON OF SIX PHONE INTERVIEWS DESIGNED TO MEASURE HEALTH-RELATED LOST PRODUCTIVE TIME AT WORK
ASTHMA MANAGEMENT AND OUTCOMES IN ITALY
SPECIFIC IMMUNOTROPIC THERAPY – ASPECTS OF COST-EFFECTIVENESS
COST-CONSEQUENCE ANALYSIS OF TIOTROPIUM VERSUS IPRATROPIUM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
ESTIMATES OF LOST PRODUCTIVE WORK TIME ASSOCIATED WITH ALLERGIC RHINITIS (AR)
ASMACARE STUDY. ASSESSMENT OF THE IMPACT OF AN INTERVENTION DESIGNED TO IMPROVE THE MANAGEMENT OF ASTHMA PATIENTS
COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL TREATMENT WITH ALMITRINE BISMESYLATE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LIFETIME COSTS OF COPD IN THE NETHERLANDS
COST-OF-ILLNESS STUDY OF PATIENTS WITH ALLERGIC ASTHMA AND SEASONAL ALLERGIC RHINITIS IN GERMANY
VARIATIONS IN COVERAGE FOR EFFECTIVE SERVICES FOR ASTHMA
EFFECTS OF DISEASE MANAGEMENT ON QUALITY OF LIFE IN PATIENTS WITH ASTHMA
ASTHMA KNOWLEDGE AND QUALITY OF LIFE (QOL) OF ADULT ASTHMATICS
IMPACT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN FRANCE
ASSESSING PATIENTS' PREFERENCES FOR CONVENTIONAL AND HOMEOPATHIC TREATMENT FOR ASTHMA–A CONJOINT ANALYSIS STUDY
ESTIMATING THE SEMI-FIXED COSTS OF A DAY-CASE EPISODE
USING CONTINGENT VALUATION IN A RCT FOR INDUCTION AND MAINTENANCE OF ANAESTHETIC AGENTS FOR DAY-CASE SURGERY
THE PSYCHOMETRIC TESTING OF THE HUNGARIAN VERSION OF THE SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE
COST-CONSEQUENCES OF ORTHOPAEDIC SURGERY IN HAEMOPHILIA PATIENTS WITH INHIBITORS
THE COST EFFECTIVENESS OF AN EXTRACORPOREAL LIVER ASSIST DEVICE FOR PATIENTS WITH FULMINANT HEPATIC FAILURE
ECONOMIC EVALUATION OF TREATING ERECTILE DYSFUNCTION IN SPAIN
THE EF-VAS
VALIDATION OF VAGINAL CONTRACEPTION ACCEPTABILITY QUESTIONNAIRE
AN ANALYSIS OF THE USEFULNESS AND TRANSPARENCY OF COST-EFFECTIVENESS LITERATURE FOR SURGICAL DEVICES AND PROCEDURES
THE BPE-PIT – AN ADAPTATION OF THE BPE-P FOR USE IN A MULTINATIONAL CLINICAL TRIAL
BENIGN PROSTATIC HYPERPLASIA-CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE
BENIGN PROSTATIC HYPERPLASIA
A RISK-ASSESSMENT MODEL FOR ERECTILE DYSFUNCTION
COST-EFFECTIVENESS ANALYSIS OF THE SPECTRON VERSUS CHARNLEY HIP PROSTHESES
INTEGRATING HEALTH ECONOMICS INTO THE PRODUCT DECISION- MAKING PROCESS
GASTROINTESTINAL DRUG POLICY, DRUG SELECTION AND RESOURCE UTILIZATION–A COMPARISON OF THE CANADIAN PROVINCES OF QUEBEC AND ONTARIO
MACRO-ECONOMIC ANALYSIS OF HEROIN MARKETS IN THE EU AND THE IMPACT OF SUBSTITUTION TREATMENT
WHAT IS A VALID PRESCRIBING INDICATOR?
USING PRESCRIBING DATA TO ESTIMATE PREVALENCE OF CHRONIC ILLNESS IN THE REPUBLIC OF IRELAND
INSURANCE CLAIMS AS A DEVICE FOR MEASURING THE PHARMACISTS SUBSTITUTION RIGHT IN A FRENCH DEPARTMENT
PILOT STUDY TO DETERMINE THE DEMOGRAPHICS, REASONS, AND TYPES OF MEDICATIONS PURCHASED IN MEXICO BY US RESIDENTS
THE USE OF ECONOMIC INFORMATION IN HOSPITAL FORMULARY DEVELOPMENT IN A FRENCH REGION
THE INFLUENCE OF UPDATING THE ISRAELI NATIONAL DRUG LIST ON AVERAGE NUMBER OF DRUGS PRESCRIBED TO A PATIENT
THE ROAD TO JAPAN/KOREA 2002
REVIEW AND ANALYSIS OF DIFFERENT METHODOLOGIES FOR THE CALCULATION AND DISTRIBUTION OF PRIMARY HEALTH CARE PHARMACEUTICAL BUDGETS IN EUROPE
BARRIERS THAT PREVENT THE USE OF ECONOMIC EVALUATIONS IN HOSPITAL FORMULARY DECISION-MAKING
PHARMACOECONOMICS OF BLOOD TRANSFUSION SAFETY MEASURES
THE CURRENT STATUS AND FUTURE PROSPECTS FOR PHARMACOECONOMICS IN GREECE
IMPACT OF FIRST GENERIC ENTRANTS ON BRAND NAME PRODUCTS
HOW RESPONSIVE ARE OUR HEALTH CENTRES?
A EUROPEAN HEALTH STATUS INDEX BASED ON PREFERENCES OF THE GENERAL PUBLIC
THE CLINICAL PHARMACIST AS A MEMBER OF THE MEDICAL WARD TEAM—A PILOT STUDY
COST OF BLOOD PRODUCTS IN GERMAN HOSPITALS
THE ECONOMIC BURDEN OF PHYSICAL INACTIVITY IN SWITZERLAND
COST-BENEFIT ANALYSIS OF PREVENTING PRESCRIBING ERRORS BY HOSPITAL PHARMACISTS
PERCEIVED QUALITY OF LIFE AND MEDICINE CONSUMPTION IN ELDERLY OUTPATIENTS
HOSPITAL READMISSIONS OF OLDER PEOPLE
CRITERIA FOR ASSESSING INTENSIVE CARE UNIT ADMISSIONS FROM THE EMERGENCY ROOM
THE USE OF ATC/DDD METHODOLOGY FOR REVIEWING COST OF DRUG EXPOSURE AT THE NATIONAL LEVEL
THE POTENTIAL BENEFITS AND DRAWBACKS OF ALLOWING DIRECT-TO-CONSUMER ADVERTISING OF PHARMACEUTICALS IN EUROPE
THE RELATIONSHIP BETWEEN NATIONAL HEALTH INSURANCE EXPENDITURE AND THE BURDEN OF DISEASE-AN EVIDENCE-BASED STUDY IN TAIWAN
THERAPEUTIC COMPARABILITY OF COX-2 INHIBITORS
ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE IN PATIENTS WITH OSTEOARTHRITIS
COST OF CARE FOR MEMBERS WITH ARTHRITIS—A MANAGED CARE PERSPECTIVE
THE COST-EFFECTIVENESS OF CELECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS IN POLAND
COST ANALYSIS OF CELECOXIB AND CONVENTIONAL NSAIDS WITH OR WITHOUT GASTROPROTECTIVE AGENTS FOR TREATMENT OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
COST-EFFECTIVENESS ANALYSIS OF USING CELECOXIB IN THE TREATMENT OF OSTEOARTHRITIS
AN ECONOMIC EVALUATION OF THE COST OF EDEMA AND SYSTOLIC BLOOD PRESSURE DESTABILIZATION IN COX-2-TREATED PATIENTS WITH OSTEOARTHRITIS AND HYPERTENSION
THE COST-EFFECTIVENESS OF INFLIXIMAB FOR SEVERE RHEUMATOID ARTHRITIS
DISABILITY, RESOURCE UTILISATION, AND WORK ABSENCES ASSOCIATED WITH OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA)
PSYCHOMETRIC VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS)
ECONOMIC ANALYSIS OF THE GUIDELINES FOR THE MANAGEMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS IN RESPIRATORY PATIENTS
DIRECT MEDICAL COST OF OSTEOPOROSIS IN THE UNITED STATES
UNITED STATES COMMUNITY PHARMACISTS' INTERVENTIONS WITH FEMALE PATIENTS REGARDING OSTEOPOROSIS
THE COST-EFFECTIVENESS OF CALCIUM AND VITAMIN D3 SUPPLEMENTATION FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURES IN SWEDEN
LONG-TERM COST-BENEFIT SIMULATION OF SIBUTRAMINE USING A MARKOV MODEL
COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION
ENOXAPARIN – A PHARMACOECONOMIC REVIEW OF ITS USE IN THROMBOEMBOLIC PROPHYLAXIS
ASSESSING THE IMPACT OF HYPERLIPIDEMIA TREATMENT WITH PRAVASTATIN AND SIMVASTATIN IN A LARGE COUNTY INSTITUTION
IMPACT OF NON-COMPLIANCE ON THE COSTEFFECTIVENESS OF STATIN THERAPY
AVAPROMISE
ENOXAPARIN – A PHARMACOECONOMIC REVIEW OF ITS USE IN ACUTE CORONARY SYNDROMES
COST-EFFECTIVENESS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION
COST-EFFECTIVENESS OF EPTIFIBATIDE IN THE UK BASED ON PURSUIT TRIAL
A PHARMACOECONOMIC ANALYSIS OF PATIENT OUTCOMES IN THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES) IN NORWAY AND CANADA
THE COST-EFFECTIVENESS OF LEVOSIMENDAN IN SEVERE LOW-OUTPUT HEART FAILURE COMPARED TO DOBUTAMINE BASED ON AN INTERNATIONAL CLINICAL TRIAL (LIDO)
A COMPARISON OF HEALTH-CARE UTILIZATION AND COSTS OF PATIENTS WITH BRADYCARDIA ONLY AND BRADYCARDIA WITH ATRIAL TACHYARRHYTHMIAS IN THE US, UK AND GERMANY
EFFECT OF AMLODIPINE TREATMENT ON CARDIOVASCULAR DISEASE-RELATED HOSPITALIZATIONS AND COSTS IN PATIENTS WITH CORONARY ARTERY DISEASE IN SPAIN
COST-OF-ILLNESS STUDY OF UNSTABLE ANGINA PECTORIS IN GERMANY
CHRONIC VENOUS INSUFFICENCY (CVI) IN POLAND–A COST OF ILLNESS STUDY
COST-EFFECTIVENESS OF AMLODIPINE TREATMENT IN PATIENTS WITH CORONARY ARTERY DISEASE IN THE U.K
ECONOMIC EVALUATION OF ENOXAPARIN IN PATIENTS WITH ACUTE MEDICAL ILLNESS
COST EFFECTIVENESS OF ENOXAPARIN VS. UNFRACTIONATED HEPARIN FOR THE PROPHYLAXIS OF DVT AND SUBSEQUENT LONG-TERM COMPLICATIONS IN TOTAL HIP REPLACEMENT SURGERY IN THE UNITED KINGDOM
A COST-EFFECTIVENESS ANALYSIS OF THE USE OF CARVEDILOL COMPARED TO BISOPROLOL IN CHRONIC HEART FAILURE
COST-EFFECTIVENESS STUDY TO DETERMINE THE IMPACT OF A TOBACCO OUTREACH PROGRAM FOR ADOLESCENTS
A HEALTH-ECONOMIC ANALYSIS OF THE USE OF AMLODIPINE IN PATIENTS UNDERGOING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY IN THE U.K
COST-EFFECTIVENESS OF ENOXAPARIN AS VENOUS THROMBOEMBOLISM PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
MODELLING THE COSTS OF ILLNESS IN THE MANAGEMENT OF CEREBROVASCULAR ACCIDENTS IN FRANCE
COSTS OF HYPERTENSION IN POLAND
A COST STUDY OF COMMON PRACTICE TREATMENT FOR CRITICAL LIMB ISCHEMIA IN MOSCOW, RUSSIA
HOW MUCH DOES ONE GRAM OF HUMAN HEART MUSCLE COST?
COST-EFFECTIVENESS ANALYSIS OF A CHEST PAIN UNIT–A RE-STRUCTURED APPROACH IN RISK STRATIFICATION OF CHEST PAIN
COST-CONSEQUENCES OF LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) COMPARED WITH HEPARIN IN UNSTABLE CORONARY ARTERY DISEASE IN JAPAN
PERSISTENCY OF TREATMENT IN PATIENTS INITIATED ON FIVE DIFFERENT CLASSES OF ANTIHYPERTENSIVE THERAPY
A POPULATION-BASED EUROPEAN STUDY OF PERSISTENCE IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS
A DECISION-ANALYSIS MODEL FOR ENHANCING MEDICATION ADHERENCE IN PATIENTS TAKING STATINS
DEVELOPMENT OF TWO INSTRUMENTS
IMPACT OF INSURANCE TYPES ON PATTERNS OF ANTIHYPERTENSIVE DRUG UTILIZATION
STOP SMOKING CESSATION TARGET
STOP SMOKING CESSATION TARGET
THE OUTCOMES OF LONG-TERM TREATMENT OF A NEW ORAL DIABETES DRUG PIOGLITAZONE (ACTOS **) IN THE MANAGEMENT OF TYPE 2 DIABETES IN FINLAND
RISK OF DIABETES AMONG RISPERIDONE AND OLANZAPINE USERS
AN ECONOMIC EVALUATION OF COMBINATION THERAPY WITH PIOGLITAZONE (ACTOS, TAKEDA) IN TYPE 2 DIABETES MELLITUS FROM A SPANISH HEALTH-CARE PERSPECTIVE
THE DIFFERENTIAL EFFECT OF SULPHONYLUREA OR BIGUANIDE DRUGS ON CARDIAC REVASCULARIZATION PROCEDURES IN DIABETICS
MODELING THE IMPACT OF A NEW ORAL ANTI-DIABETIC TREATMENT ON DIABETES COMPLICATION COSTS IN FRANCE
COST-EFFECTIVENESS OF PIOGLITAZONE (ACTOS®, TAKEDA) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN SWEDEN
THE LIFETIME DIRECT MEDICAL COSTS OF MANAGING DIABETES AND ITS COMPLICATIONS IN FRANCE
A POPULATION STUDY OF HEALTH-CARE COSTS ASSOCIATED WITH HYPOGLYCAEMIA
THE EVENT AND STATE COST OF COMPLICATIONS OF DIABETES IN THE NETHERLANDS
A PHARMACOECONOMIC MODEL OF HbA1c CONTROL IN THE TREATMENT OF TYPE 2 DIABETES
HEALTH AND ECONOMIC OUTCOMES OF A NEW ORAL DIABETES DRUG, PIOGLITAZONE (ACTOS*NF, TAKEDA), IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN NORWAY
CLINICAL BENEFITS AND COST-OFFSETS OF COMBINATION THERAPY WITH NATEGLINIDE PLUS METFORMIN VERSUS METFORMIN ALONE IN DIABETES IN THE NETHERLANDS
ASSESSING PATIENT CARE AND COST OF PATIENTS WITH TYPE 2 DIABETES IN GERMANY—AN ANALYSIS ACROSS DIFFERENT TREATMENT TYPES
AN ASSESSMENT OF THE COST-EFFECTIVENESS OF PIOGLITAZONE (ACTOS*NF, TAKEDA) IN TYPE 2 DIABETES MELLITUS IN DENMARK
THE COST OF TREATING DIABETIC FOOT ULCERS (DFU) WITH APLIGRAF IN THE NETHERLANDS
BUDGETARY IMPACT OF TREATMENT GUIDELINES—THE EXAMPLE OF TYPE 2 DIABETES
AN ECONOMIC ANALYSIS OF IRBESARTAN IN TYPE II DIABETIC NEPHROPATHY
TREATMENT CHANGE FOLLOWING HEMOGLOBIN A1c TEST RESULTS AMONG DIABETIC PATIENTS
TRENDS IN USE OF ANTIDIABETICS IN THE CZECH REPUBLIC
A SIMULATION MODEL TO CALCULATE LONG-TERM COSTS AND LIFE EXPECTANCY DEPENDENT ON POST PRANDIAL BLOOD GLUCOSE LEVELS IN DIABETES PATIENTS
HUMANISTIC IMPACT OF HYPERGLYCEMIA IN TYPE 1 DIABETES MELLITUS
EVALUATION OF A GENERIC QOL INSTRUMENT (KINDL) FOR SELF-ASSESSMENT OF QOL IN SINGAPOREAN CHILDREN WITH DIABETES
PHARMACEUTICAL AND HOSPITAL EXPENDITURE FOR ANTI-DYSPEPTIC TREATMENT
PHARMACOECONOMIC ASSESSMENT OF RABEPRAZOLE IN PEPTIC ULCER IN RUSSIA
ECONOMIC DIFFERENTIATION BETWEEN PPIS IN THE TREATMENT OF REFLUX ESOPHAGITIS RELATED TO GERD
THE IMPACT OF THE USE OF NEXIUM ON THE OVERALL PPI BUDGET IN GREECE
HEALTH STATE UTILITIES IN GERD PATIENTS WITH HEARTBURN A STUDY IN GERMANY AND SWEDEN
LONG TERM CLINICAL CONSEQUENCES OF ND
COSTS AND CONSEQUENCES OF OLOPATADINE 0.1% VERSUS LEVOCABASTINE 0.05% IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS
COSTS AND CONSEQUENCES OF OLOPATADINE 0.1% VERSUS CROMOLYN SODIUM 2% IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS
WELFARE COSTS OF VISUAL IMPAIRMENT
COSTS AND CONSEQUENCES OF LASIK, GLASSES AND CONTACT LENSES IN MILD TO MODERATE MYOPIA—A SPANISH SOCIETAL APPROACH
PROSTAMIDES VS. COMBINATION PRODUCTS FOR GLAUCOMA TREATMENT
THE BURDEN OF AGE-RELATED MACULAR DEGENERATION—RESULTS OF A COHORT STUDY IN TWO FRENCH REFERRAL CARE CENTERS
QUALITY OF LIFE OF FRENCH PATIENTS TREATED FOR PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION
THE SOCIETAL COST OF ATOPIC DERMATITIS IN GERMANY
IS NON-CONTACT NORMOTHERMIC WOUND THERAPY COST-EFFECTIVE FOR THE TREATMENT OF STAGE 3 AND 4 PRESSURE ULCERS?
PSORIASIS AND EVERYDAY LIFE
THE WILLINGNESS TO PAY FOR PHARMACOTHERAPY OF ATOPIC DERMATITIS
ASSOCIATION OF FAMILY HARDINESS WITH WORK PRODUCTIVITY AND ACTIVITY IN FAMILIES OF PEDIATRIC PATIENTS WITH EPILEPSY
COMPARISON OF ADVERSE REACTION REPORTS FOR RIVASTIGMINE AND DONEPEZIL USING THE FDA'S ADVERSE EVENT REPORTING SYSTEM
COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSON'S DISEASE
THE IMPACT OF DRUG INTERACTIONS ON HOSPITALIZATION RATES FOR ALZHEIMER'S PATIENTS TREATED WITH DONEPEZIL
THE COST OF SECONDARY STROKE IN POLAND
ASSESSING THE COSTS OF PARKINSON'S DISEASE IN GERMANY
ESTIMATION OF THE COSTS OF MULTIPLE SCLEROSIS BASED ON 157 FRENCH PATIENTS
IMPLICATIONS OF PRESCRIBING FOR PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
IMPACT OF RIVASTIGMINE ON ANTIPSYCHOTIC UTILIZATION AND COST IN ALZHEIMER'S DISEASE
CONCOMITANT DRUG USE IMPLICATIONS IN ALZEIMER'S DISEASE PATIENTS USING DONEPEZIL
DISEASE MANAGEMENT IN MIGRAINE AND TENSION-TYPE HEADACHE — RESULTS OF A SOCIO-ECONOMIC PILOT STUDY
TREATMENT AND HEALTH-CARE SATISFACTION AMONG PEOPLE WITH MIGRAINE HEADACHES
TREATMENT AND QUALITY OF LIFE AMONG PEOPLE WITH MIGRAINES
QUALITY OF LIFE OF WOMEN SUFFERING FROM MENSTRUAL MIGRAINE AND RELATIONSHIP WITH MOOD
COST-EFFECTIVENESS OF THERAPY FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)